Pilot trial of N-acetylcysteine and tigecycline as a catheter-lock solution for treatment of hemodialysis catheter-associated bacteremia.

Saima Aslam, Barbara W Trautner, Venkat Ramanathan, Rabih O Darouiche

Journal: Infection control and hospital epidemiology 2008;29(9):894-7

PMID: 18643743

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

We evaluated a catheter-lock solution consisting of N-acetylcysteine, tigecycline, and heparin for catheter salvage in patients with hemodialysis catheter-associated bacteremia. Eighteen case patients received the catheter-lock solution for 14 days plus systemic antibiotic therapy. Treatment was successful for 15 (83%) of the 18 case patients within 90 days of follow-up, with a median catheter retention interval of 64.5 days.

Address: Sections of Infectious Disease, Department of Medicine, Baylor College of Medicine, the Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas 77030, USA. [email protected]

DOI: 10.1086/590192

Link outs

Free resources

Medical:

Subscription / membership required

Full Text Sources:

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linko...

MeSH Terms: Acetylcysteine, Anti-Bacterial Agents, Bacteremia, Catheterization, Female, Gram-Negative Bacterial Infections, Gram-Positive Bacterial Infections, Humans, Male, Middle Aged, Minocycline, Pilot Projects, Prospective Studies, Renal Dialysis, Tigecycline, Treatment Outcome